{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-040885","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.589352+00:00","generated_at":"2026-06-05T21:44:15.155369+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vaccinex enters 8 ActivMAb agreements including 3 major pharma companies for complex membrane targets","bullets":["Eight new antibody discovery agreements integrate ActivMAb platform, with 3 major pharma/biotech companies and 5 strategic antibody-service partners.","ActivMAb 'Antigen Virus' application targets difficult multi-pass membrane proteins such as GPCRs, ion channels, and chemokine receptors.","Technology enables antibody drug conjugate (ADC) development for cancer; platform uses purified viral presentation for efficient selection.","Agreements signed within last 3 months; CEO cites renewed market optimism after two-year biotech downturn as driver of interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-040885","json":"https://secwatch.observer/filing/0001193125-24-040885.json","markdown":"https://secwatch.observer/filing/0001193125-24-040885.md","text":"https://secwatch.observer/filing/0001193125-24-040885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524040885/0001193125-24-040885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524040885/d781705d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:44:15.155369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}